(Golden Oldie) The effectiveness of trigger point dry needling for musculoskeletal conditions by physical therapists: a systematic review and meta-analysis

Key points

1. 01Short-term pain reduction vs. sham or no treatment: low-quality evidence, moderate effect (SMD -0.70, 95% CI: -1.06 to -0.34)
2. 02Pressure pain threshold improvement vs. sham or no treatment: very low-quality evidence, moderate effect (SMD 0.80, 95% CI: 0.32 to 1.27)
3. 03Functional outcomes vs. sham or no treatment: low-quality evidence, small effect (SMD -0.44, 95% CI: -0.85 to -0.04)
4. 04Compared to other physical therapy treatments, dry needling shows a small pain advantage (SMD -0.43) but no functional outcome advantage (SMD -0.01)
5. 05No statistically significant benefit for pain at 6-12 months (SMD -0.26, 95% CI: -0.58 to 0.06)

How it was conducted

Design

Systematic review and meta-analysis (PRISMA guidelines)

Databases searched

MEDLINE, AMED, CINAHL, Embase

Included studies

13 RCTs involving a total of 723 participants

Conditions covered

Neck pain (6 studies), myofascial pain (2), fibromyalgia (1), low back pain (1), ankle instability (1), post-surgical shoulder pain (1), post-TKA pain (1)

Quality assessment

PEDro scale (scores 4-9, median 7) and GRADE approach

Primary outcomes

Pain, pressure pain threshold (PPT), and functional outcomes at immediate to 12-week and 6-12 month follow-up

What they found

• Pain vs. control/sham (0-12 weeks): low-quality evidence, SMD -0.70 (95% CI: -1.06, -0.34), I2 = 78%, p<0.001
• PPT vs. control/sham (0-12 weeks): very low-quality evidence, SMD 0.80 (95% CI: 0.32, 1.27), I2 = 87%, p = 0.001
• Functional outcomes vs. control/sham (0-12 weeks): low-quality evidence, SMD -0.44 (95% CI: -0.85, -0.04), I2 = 79%, p = 0.03
• Pain vs. control/sham (6-12 months): moderate-quality evidence, SMD -0.26 (95% CI: -0.58, 0.06), I2 = 11%, p = 0.11 (not statistically significant)
• Functional outcomes vs. control/sham (6-12 months): low-quality evidence, SMD -0.32 (95% CI: -0.62, -0.02), I2 = 0%, p = 0.03
• Pain vs. other treatments (0-12 weeks): moderate-quality evidence, SMD -0.43 (95% CI: -0.77, -0.10), I2 = 67%, p = 0.01
• PPT vs. other treatments (0-12 weeks): very low-quality evidence, SMD 0.61 (95% CI: 0.08, 1.14), I2 = 85%, p = 0.02
• Functional outcomes vs. other treatments (0-12 weeks): very low-quality evidence, SMD -0.01 (95% CI: -0.49, 0.47), I2 = 70%, p = 0.97 (no effect)
• Average raw treatment effect on pain within 12 weeks was 1.27 VAS points better with dry needling vs. control/sham (below the 2.0-point clinically meaningful threshold)
• No trial was able to blind the treating therapist; only 3 of 13 trials (23%) blinded participants via sham needling

Limitations

• Overall GRADE evidence quality was very low to moderate, meaning further research is likely to change effect estimates
• High heterogeneity in 5 of 8 meta-analyses (I2 up to 94%), driven by diverse conditions, comparison groups, and follow-up timepoints
• Only 2 studies had 6-12 month follow-up data, making long-term conclusions unreliable
• Results are limited to dry needling performed by physical therapists and cannot be generalized to other practitioners or training contexts

Why it matters

For patients

If you have musculoskeletal pain, dry needling by a physical therapist may offer some short-term pain relief beyond what no treatment or placebo provides, but it is unlikely to improve your physical function more than other standard physical therapy techniques.

For clinicians

Dry needling can be a reasonable short-term adjunct for pain and pressure pain threshold in appropriate musculoskeletal patients, but evidence does not support it over other manual therapy techniques for functional improvement, and long-term benefit is unproven.

For readers

This 2017 meta-analysis (13 RCTs, 723 participants) provides the first evidence synthesis focused specifically on physical therapist-delivered dry needling, finding short-term pain benefits over sham but no functional advantage over other PT treatments.